​

Heron Therapeutics (HRTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HRTX Stock Forecast

Heron Therapeutics (HRTX) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 198.51% increase from the last price of $2.01.

$1 $2 $3 $4 $5 $6 High: $6 Avg: $6 Low: $6 Last Closed Price: $2.01

HRTX Stock Rating

Heron Therapeutics stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 18 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 18 Strong Sell Sell Hold Buy Strong Buy

HRTX Price Target Upside V Benchmarks

TypeNameUpside
StockHeron Therapeutics198.51%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts111
Avg Price Target$6.00$6.00$6.00
Last Closing Price$2.01$2.01$2.01
Upside/Downside198.51%198.51%198.51%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2512---3
May, 2512---3
Apr, 2512---3
Mar, 2512---3
Feb, 2512---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 09, 2025Brandon FolkesH.C. Wainwright$6.00$2.12183.02%198.51%
May 16, 2024Carl ByrnesNorthland Securities$9.00$3.22179.50%347.76%
Mar 13, 2024Serge BelangerNeedham$5.00$3.0166.11%148.76%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 09, 2025H.C. WainwrightBuyinitialise
Jun 12, 2024Rodman & RenshawBuyinitialise
Mar 13, 2024NeedhamBuyBuyhold
Nov 15, 2023NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.47$-2.21$-1.24$-0.80$-0.09----
Avg Forecast$-2.47$-2.28$-1.85$-0.87$-0.13$-0.05$0.05$0.21$0.36
High Forecast$-2.40$-2.22$-1.78$-0.83$-0.12$-0.04$0.07$0.26$0.38
Low Forecast$-2.55$-2.37$-1.92$-0.90$-0.13$-0.05$0.04$0.16$0.34
Surprise %--3.07%-32.97%-8.05%-30.77%----

Revenue Forecast

$50M $100M $150M $200M $250M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$88.64M$86.35M$107.67M$127.04M$144.28M----
Avg Forecast$87.61M$91.84M$104.90M$123.59M$140.89M$157.96M$180.36M$212.65M$254.90M
High Forecast$90.02M$94.37M$108.21M$124.31M$141.34M$164.06M$185.23M$214.95M$263.24M
Low Forecast$85.74M$89.89M$102.11M$122.87M$140.44M$151.87M$175.48M$210.35M$245.50M
Surprise %1.18%-5.98%2.64%2.80%2.41%----

Net Income Forecast

$-300M $-220M $-140M $-60M $20M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-224.43M$-217.66M$-134.52M$-110.56M$-13.58M----
Avg Forecast$-232.41M$-228.29M$-225.20M$-110.56M$-17.75M$-6.74M$7.44M$29.01M$49.73M
High Forecast$-185.93M$-182.63M$-180.16M$-88.45M$-16.95M$-6.15M$9.73M$35.87M$51.84M
Low Forecast$-278.90M$-273.94M$-270.24M$-132.67M$-18.56M$-7.32M$5.15M$22.15M$47.35M
Surprise %-3.44%-4.65%-40.27%--23.51%----

HRTX Forecast FAQ

Is Heron Therapeutics stock a buy?

Heron Therapeutics stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 18 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Heron Therapeutics is a favorable investment for most analysts.

What is Heron Therapeutics's price target?

Heron Therapeutics's price target, set by 18 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 198.51% change from the previous closing price of $2.01.

How does Heron Therapeutics stock forecast compare to its benchmarks?

Heron Therapeutics's stock forecast shows a 198.51% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and outperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Heron Therapeutics over the past three months?

  • June 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Heron Therapeutics’s EPS forecast?

Heron Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.05, marking a -44.44% decrease from the reported $-0.09 in 2024. Estimates for the following years are $0.05 in 2026, $0.21 in 2027, and $0.36 in 2028.

What is Heron Therapeutics’s revenue forecast?

Heron Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $157.96M, reflecting a 9.48% increase from the reported $144.28M in 2024. The forecast for 2026 is $180.36M, followed by $212.65M for 2027, and $254.9M for 2028.

What is Heron Therapeutics’s net income forecast?

Heron Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-6.737M, representing a -50.39% decrease from the reported $-13.58M in 2024. Projections indicate $7.44M in 2026, $29.01M in 2027, and $49.73M in 2028.